8-KOther EventsExhibits & Filings

BRISTOL MYERS SQUIBB CO 8-K Report, Corporate Update (Sep 24, 2007)

Filed September 24, 2007For Securities:BMYCELG-RIBMYMP

Summary

Bristol-Myers Squibb Company (BMY) announced on September 24, 2007, that it has entered into a definitive agreement to acquire Adnexus Therapeutics, a privately held company specializing in a novel therapeutic class known as Adnectins. The acquisition is valued at a gross purchase price of $430 million, with a net price of $415 million after accounting for Adnexus' net cash at closing. This strategic move signifies Bristol-Myers Squibb's commitment to expanding its pipeline with innovative biologic therapies. Adnectins represent a new platform that could potentially lead to the development of next-generation treatments, offering significant potential for future growth and diversification of the company's product portfolio. Investors should monitor the integration of Adnexus' technology and the progress of its Adnectin-based drug candidates.

Key Highlights

  • 1BMY to acquire Adnexus Therapeutics, a privately held biotech company.
  • 2Acquisition price: $430 million gross, $415 million net (after deducting Adnexus' net cash).
  • 3Adnexus Therapeutics is a developer of a new therapeutic class called Adnectins.
  • 4The deal aims to strengthen BMY's pipeline with innovative biologic therapies.
  • 5The announcement was made via a press release filed as an exhibit to the 8-K.
  • 6This acquisition represents a strategic investment in novel drug development platforms.

Frequently Asked Questions

The primary purpose of the acquisition is to enhance Bristol-Myers Squibb's drug development pipeline by incorporating Adnexus Therapeutics' novel Adnectin technology, which represents a new class of biologics.

Adnectins are a new therapeutic class of biologics developed by Adnexus Therapeutics. Their significance lies in their potential to create next-generation treatments, offering an innovative platform for drug development.

The gross purchase price for Adnexus Therapeutics is $430 million. After deducting Adnexus' net cash balances at closing, the net purchase price is $415 million.

More details about this transaction can be found in the press release issued by Bristol-Myers Squibb Company and Adnexus Therapeutics on September 24, 2007, which is filed as Exhibit 99.1 to this Form 8-K filing.